Publications

2026     

• Chan, M, Zhu, S, Russell, Z, Arora, S, Arakaki, A, Kumasaka, D, Szulzewsky, , Michealraj, A, Holland, EC and Gujral, TS. A Systems approach identifies MERTK as a therapeutic vulnerability in ZFTA-RELA-driven ependymomas. Proc Natl Acad Sci U S A. 2026. In Press.

• Vaz, J, Zhu, S, Useche, M, Shih, L, Marchiano, E, Beronja, S, Clurman, BE, Rodriguez, C, Barber, B, Chan, M and Gujral, TS. 2026. Subtype-Specific Dependencies and Drug Vulnerabilities Enable Precision Therapeutics in Head and Neck Cancer. bioRxiv. Pubmed.

• Saifudeen M, Zhu S, Liang S, Eason M, Goupil A, Mische DF, Loch CM, Ma H, Chan M, and Gujral TS. Comprehensive profiling of clinically approved kinase inhibitors reveals opportunities for drug repurposing and for uncovering new biology. Nat Biotechnology. 2026. Manuscript Accepted.

2025     

• Nishida-Aoki, N, Zhu, S, Chan, M, Kang, Y, Fujita, M, Jiang, X, McCabe, M, Vaz, JM, Davidson, NE, Ghajar, CM, Hansen, K, Welm, A, Pillarisetty, VG and Gujral, TS. Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. Cell Reports Medicine. 2025.Sep 19:102357. Pubmed.

• Chan, M, and Gujral, TS. Beyond genomics: 3D microtumor assays for rapid, clinically relevant functional drug testing. Oncogene. (50):4910-4915.  Pubmed.

• Chan, M, Zhu, Z, Nukaya, M, Ferreira, L, Ronnekleiv-Kelly, S, Riehle, KJ, Scott, JD, Yeung, RS and Gujral, TS. DNAJ-PKAc Fusion Heightens PLK1 Inhibitor Sensitivity in Fibrolamellar Carcinoma. Gut. 2025. 24 April 2025. doi: 10.1136/gutjnl-2024-334274. Pubmed.

• Stepanov, I, Gottshall, NR, Ahmadianyazdi, A, Sinha, D, Lockhart, EJ, Nguyen, TN, Hassan, S, Horowitz, LF, Yeung, RS., Gujral, TS. and Folch, A.  Low-Cost Robotic Manipulation of Live Microtissues for Cancer Drug Testing. Science Advances. 2025. 11,eads1631. Pubmed.

• Gritti, I, Wan, J, Weeresekara, V, Vaz, JM, Tarantino, G, Holgersen, T, Vijay, BV, Kammula, AV, Kattel, P, Zhu, S, Vu, P, Chan, M,  Wu, M, Gordan, JD, Patra, KC, Silveira, VS, Manguso, RT, Wein, MN,  Ott, CJ, Qi, J, Liu, D, Sakamoto, K, Gujral, TS*, and Bardeesy, N*. DNAJB1-PRKACA fusion drives fibrolamellar liver cancer through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogramming. Cancer Discovery.  2025 Apr 2;15(4):862. Pubmed. * co-corresponding

• Arora, S, Nuechterlein, N, Jensen, M, Glatzer, G, Sievers, S, Varadharajan, S, Korshunov, A, Sahm, F, Mack, SC, Taylor, MD, Gujral, TS, and Eric C Holland. Integrated transcriptomic landscape of medulloblastoma and ependymoma reveals novel tumor subtype-specific biology, Neuro-Oncology, 2025. Oct 24:noaf251. Pubmed.

• Paatela EM, St Amant FG, Hamm DC, Bennett SR, Gujral TS, van der Maarel SM, Tapscott SJ. A discrete region of the D4Z4 is sufficient to initiate epigenetic silencing. Hum Mol Genet. 2025 Jul 8:ddaf114.

• Nukaya, M, Carney, PR, Cafferty, C, Zahed, K, Yun, I, Al-Adra, DP, Kazim, NA, Farghli, AR, Chan, M, Stram, A, Kratz, JD, Berres, ME, Yen, A, Gujral, TS, Sethupathy,  P, Bradfield, Ca, Ronnekleiv-Kelly, SM.CDK7 is a novel therapeutic target in fibrolamellar carcinoma. iScience. 2025. 28 (12):113925. Pubmed.

• Pang, Y, Li, Q, Sergi, Z, Yu, G, Kim, O, Lu, P, Chan, M, Sang, X, Wang, H, Ranjan, A, Robey, RW, Soheilian, F, Tran, B, Núñez, FJ, Zhang, M, Song, H, Zhang, W, Davis, D, Gilbert, MR, Gottesman, M, Liu, Z, Khan, J, Thomas, CJ, Castro, MG, Gujral, TS, and Wu, J. Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib. iScience. 2025. 28(4):112283. Pubmed. 

2024

• Long, D, Chan, M, Han, M, Kamdar, Z, Ma, RK, Tsai, P, Francisco, AB, Barrow, J, Shackelford, DB, Yarchoan, M, McBride, MJ, Orre, LM, Vacanti, NM, Gujral, TS, and Sethupathy, P.  Proteo-metabolomics and patient tumor slice experiments point to amino acid centrality for rewired mitochondria in fibrolamellar carcinoma. Cell Reports Medicine. 2024. Aug.  28101699. Pubmed.  

• Ho, C, Zhu, S, Gooley, T, Gujral, T.S, Lynch, RC, Poh, C, Shadman, M, Smith, SD, Tseng, Y and Gopal, AK. A phase 2 study of frontline pembrolizumab in follicular lymphoma. EJHaem. 2024 Oct 10;5(6):1173-118. Pubmed. 

• Nguyen, RN, Horowitz, L, Krilov, T, Lockhardt, E, Kenerson, H, Gujral, TS, Yeung, RS, Arroyo-Curras, N, Folch, A. Label-free, real-time monitoring of cytochrome C drug responses in microdissected tumor biopsies with a multi-well aptasensor platform. Science Advances. 10,eadn5875(2024). Pubmed.  

• Ma, RK, Tsai, P, Farghli, AR, Shumway, A, Kanke, M, Gordan, JD, Gujral, TS, Vakili, K, Nukaya, M, Noetzli, L, Ronnekleiv-Kelly, S, Broom, W, Barrow, J, Sethupathy, P. DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma. PLoS Genetics. 2024. Mar 21;20(3):e1011216. Pubmed. 

• Lockhart, EJ, Horowitz, LF, Zhu, S, Nguyen, T, Mehrabi, M, Gujral, TS, and Folch, A. Drug testing of liver microdissected tumors using a multiwell microfluidic platform with valved hydodynamic traps. Lab on a Chip. 2024 May 14;24(10):2683-2699.  Pubmed.

2023

• Chan, M#, Kang, Y#, Osborne, S, Zager, M and Gujral, TS. KinCytE- a Kinase to Cytokine Explorer to Identify Molecular Regulators and Potential Therapeutic Opportunities. eLife. 2023. 12:RP91472. Pubmed. 

• Olson, AT,  Kang, Y, Ladha, AM,  Zhu, S, Lim, CB, Nabet, B, Lagunoff, M, Gujral, TS*, and Geballe, AP*. Polypharmacology-based kinome screen identifies new regulators of KSHV reactivation. Plos Pathogens. 2023. 19(9), e1011169. Pubmed. *co-corresponding.

• Poh C, Chow VA, Lynch RC, Ujjani CS, Shadman M, Till BG, Raghunathan V, Warren EH, Gauthier J, Smith SD, Gujral T, Morishima C, Wu Q, Voutsinas JM, Sperling A, Dzon J, Maloney DG, Gopal AK. Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis. Blood. 2023 Dec 1;142 (Supplement 1):2129

• Huang, YL., Dickerson, LK., Kenerson, H, Jiang, X, Pillarisetty, V, Tian, Q, Hood, L, Gujral, TS* and Yeung, R.S., 2023. Organotypic Models for Functional Drug Testing of Human Cancers. BME frontiers, 4, p.0022. Pubmed. *co-corresponding.

• Mossa, F, Robesti, D, Ramachandran, S, Corey, E, Titus, MA, Kang, Y, Zhang, J, Briganti, A, Montorsim F, Vellano, CP, Marszalek, JR, Frigo, DE, Logothetis, CJ, Gujral, TS, and Dondossola, E. Subtype and site specific-induced metabolic vulnerabilities in prostate cancer. Molecular Cancer Research. 2023. 21 (1): 51–61. Pubmed
  

2022

• Szulzewsky, F Arora, S, Arakaki, A, Sievers, P, Bonin, D, Paddison, P, Sahm, F, Cimino, PJ, Gujral, TS,  Holland, EC. 2022. Expression of YAP1-MAML2 and constitutively active YAP1 drive the formation of meningioma-like tumors in mice that resemble NF2-mutant meningiomas. Genes & Development. Pubmed.

• Sullivan, KM, Jiang, X, Guha, P, Lausted, C, Carter, JA, Hsu, C, Labadie, KP, Kohli, K, Kenerson, HL, Daniel, SK, Yan, X, Meng,C, Chan, M, Abbasi, A, Seo, D, Park, JO, Crispe, N, Yeung, RS,  Kim, TS,  Gujral, TS, Tian, Q, Katz, sc, and Pillarisetty, VG. 2022. Blockade of interleukin-10 potentiates antitumor immune function in human colorectal cancer liver metastases. Gut. Pubmed. 

• Chan, M, Holland, E, and Gujral, TS.  Olverembatinib inhibits SARS-CoV-2-Omicron variant-mediated cytokine release.  EMBO molecular medicine. 2022. May 17. e15919. Pubmed

• Kang, Y,  Vijay, S, and Gujral, TS. Deep Neural Network Modeling Identifies Biomarkers of Response to Immune-checkpoint Therapy. iScience. 2022. 25 (5) May 20, 104228. Pubmed

• Nishida-Aoki, N, and Gujral, TS. Polypharmacologic Reprogramming of Tumor-Associated Macrophages toward an Inflammatory Phenotype. Cancer Research. 2022. Feb 1. 13:canres.1428.202. Pubmed

2021     

• Bello T, Paindelli C, Diaz-Gomez LA, Melchiorri A , Mikos AG, Nelson PS, Dondossola E, and Gujral TS. Computational modeling identifies multi-targeted kinase inhibitors as effective therapies for castration-resistant prostate cancer.  Proc Natl Acad Sci U S A.  2021. October 5, 118 (40) e2103623118. Pubmed.

• Bello, T,  Chan, M, Golkowski, M, Xue, AG, Khasnavis, N, Ceribelli, M, Ong,S, Thomas, C, and Gujral, TS. KiRNet: Kinase-centered network propagation of pharmacological screen results. Cell Reports Methods. 2021. 100007. Pubmed

• Chan, M, Vijay, S., McNevin, J, McElrath, JM, Holland, EC, and Gujral, TS. Machine Learning Identifies Molecular Regulators and Inhibitors for COVID19-induced Cytokine Release. Molecular Systems Biology. 2021. Sep;17 (9):e10426. Pubmed

• Arakaki, AKS, Szulzewsky, F, Gilbert, M, Gujral, TS, and Holland, EC. Utilizing Preclinical Models to Develop Targeted Therapies for Rare CNS Cancers. 2021. Neuro-Oncology. 23 (5) S4–S15. Pubmed

• Arakaki, AKS.,  Pan, W, Wedegaertner, H,  Roca-Mercado, I, Chinn, L, Gujral, TS, and Trejo, J. α-arrestin ARRDC3 tumor suppressor function is linked to GPCR-induced TAZ activation and breast cancer metastasis. Journal of Cell Science. 2021. Mar 15;jcs.254888. Pubmed

• Horowitz, LF, Rodriguez, AD, Au-Yeung, A, Bishop, KW, Barner, LA, Mishra, G, Raman, A, Delgado, P, Liu, JTC, Gujral, TS, Mehrabi, M, Yang, M, Pierce, R, and Folch, A. Microdissected “cuboids” for microfluidic drug testing of intact tissues. Lab on a Chip. 2021. Jan 5;21(1):122-142. Pubmed.